# A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.

> **NCT00530764** · PHASE2 · COMPLETED · sponsor: **GW Pharmaceuticals Ltd** · enrollment: 360 (actual)

## Conditions studied

- Palliative Care
- Pain
- Cancer

## Interventions

- **DRUG:** Sativex Low Dose
- **DRUG:** Sativex Medium Dose
- **DRUG:** Sativex High Dose

## Key facts

- **NCT ID:** NCT00530764
- **Lead sponsor:** GW Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2013-06-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00530764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00530764, "A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00530764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*